Solid Self-Microemulsifying Drug Delivery System for Improved Oral Bioavailability of Relugolix: Preparation and Evaluation

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Date 2025 Jan 31

PMID 39886543

Authors

Zi-Lin Li

Guo-Xing Deng

Chuan-Zhou Fang

Yue-Qi Zhao

Jing Yuan

Liang Chen

Hai-Jun Zhong

Feng Guo

Affiliations

Soon will be listed here.

Abstract

Purpose: To improve the oral absorption of relugolix (RLGL), which has low oral bioavailability due to its low solubility and being a substrate of P-glycoprotein (P-gp). A solid self-microemulsifying drug delivery system of relugolix (RLGL-S-SMEDDS) was prepared and evaluated in vitro and in vivo.

Methods: The composition of the solid self-microemulsifying drug delivery system (S-SMEDDS) was selected by solubility study and pseudo-ternary phase diagram, and further optimized by Design-Expert optimization design. The optimized RLGL-S-SMEDDS were evaluated in terms of particle size, zeta potential, morphology analysis, thermodynamic stability, drug release, flow properties, transporter pathways in Caco-2 cells, the influence of excipients on the intestinal transporters, transport within Caco-2 cell monolayers and transport in lymphocyte. In vivo pharmacokinetic study and toxicological study were also conducted.

Results: The optimum formulation for self-microemulsifying drug delivery system (SMEDDS) consists of Ethyl Oleate (26% of the weight), Solutol HS15 (49% of the weight), Transcutol HP (25% of the weight) and loaded relugolix (4.8 mg/g). The S-SMEDDS was then formed by adsorbing 2.4 g of SMEDDS onto 1 g of hydrophilic-200 silica. In phosphate buffered saline (PBS) (pH 6.8) release medium containing 1% tween 80, the vitro release studies showed 86% cumulative drug release for RLGL-S-SMEDDS and 3.6% cumulative drug release for RLGL suspensions. In vitro cellular uptake experiments revealed that the uptake of RLGL-S-SMEDDS by Caco-2 cells was three times higher than that of free RLGL, and that S-SMEDDS can enhance the drug absorption through lymphatic absorption and inhibition of intestinal transporter. In vivo pharmacokinetic evaluation demonstrated that the oral bioavailability of RLGL-S-SMEDDS was 1.9 times higher than that of RLGL-suspensions. There was no apparent cardiac, hepatic, splenic, pulmonary or renal toxicity on the surface discovered by pathological analysis after oral administration.

Conclusion: It is evident that S-SMEDDS may be a safe and effective method to improve oral absorption of drugs with low oral bioavailability.

References

Huirne J, Lambalk C . Gonadotropin-releasing-hormone-receptor antagonists. Lancet. 2001; 358(9295):1793-803. DOI: 10.1016/S0140-6736(01)06797-6. View

Pouton C, Porter C . Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2007; 60(6):625-37. DOI: 10.1016/j.addr.2007.10.010. View

Li F, Hu R, Wang B, Gui Y, Cheng G, Gao S . Self-microemulsifying drug delivery system for improving the bioavailability of huperzine A by lymphatic uptake. Acta Pharm Sin B. 2017; 7(3):353-360. PMC: 5430757. DOI: 10.1016/j.apsb.2017.02.002. View

Beloqui A, Brayden D, Artursson P, Preat V, des Rieux A . A human intestinal M-cell-like model for investigating particle, antigen and microorganism translocation. Nat Protoc. 2017; 12(7):1387-1399. DOI: 10.1038/nprot.2017.041. View

Verma R, Kaushik D . Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential. Drug Deliv. 2020; 27(1):756-771. PMC: 7269045. DOI: 10.1080/10717544.2020.1760961. View

Rahman M, Hussain A, Sarfaraj Hussain M, Aamir Mirza M, Iqbal Z . Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS). Drug Dev Ind Pharm. 2012; 39(1):1-19. DOI: 10.3109/03639045.2012.660949. View

Liu S, Cao Y, Ma L, Sun J, Ramos-Mucci L, Ma Y . Oral antimicrobial peptide-EGCG nanomedicines for synergistic treatment of ulcerative colitis. J Control Release. 2022; 347:544-560. DOI: 10.1016/j.jconrel.2022.05.025. View

Moreau H, Bernadac A, Gargouri Y, Benkouka F, Laugier R, Verger R . Immunocytolocalization of human gastric lipase in chief cells of the fundic mucosa. Histochemistry. 1989; 91(5):419-23. DOI: 10.1007/BF00493829. View

Zhang H, Yao M, Morrison R, Chong S . Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res. 2003; 26(9):768-72. DOI: 10.1007/BF02976689. View

10.

Gershanik T, Benita S . Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm. 2000; 50(1):179-88. DOI: 10.1016/s0939-6411(00)00089-8. View

11.

Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N . Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2020; 115(2):397-405. DOI: 10.1016/j.fertnstert.2020.07.055. View

12.

Hubatsch I, Ragnarsson E, Artursson P . Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007; 2(9):2111-9. DOI: 10.1038/nprot.2007.303. View

13.

Nazzal S, Khan M . Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int J Pharm. 2006; 315(1-2):110-21. DOI: 10.1016/j.ijpharm.2006.02.019. View

14.

Lee J, Lee G . Formulation Approaches for Improving the Dissolution Behavior and Bioavailability of Tolvaptan Using SMEDDS. Pharmaceutics. 2022; 14(2). PMC: 8879311. DOI: 10.3390/pharmaceutics14020415. View

15.

Das S, Lee S, Chia V, Chow P, Macbeath C, Liu Y . Development of microemulsion based topical ivermectin formulations: Pre-formulation and formulation studies. Colloids Surf B Biointerfaces. 2020; 189:110823. DOI: 10.1016/j.colsurfb.2020.110823. View

16.

Bandyopadhyay S, Katare O, Singh B . Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Colloids Surf B Biointerfaces. 2012; 100:50-61. DOI: 10.1016/j.colsurfb.2012.05.019. View

17.

Setthacheewakul S, Kedjinda W, Maneenuan D, Wiwattanapatapee R . Controlled release of oral tetrahydrocurcumin from a novel self-emulsifying floating drug delivery system (SEFDDS). AAPS PharmSciTech. 2010; 12(1):152-64. PMC: 3066365. DOI: 10.1208/s12249-010-9568-8. View

18.

Kollipara S, Gandhi R . Pharmacokinetic aspects and in vitro-in vivo correlation potential for lipid-based formulations. Acta Pharm Sin B. 2015; 4(5):333-49. PMC: 4629105. DOI: 10.1016/j.apsb.2014.09.001. View

19.

Na Y, Wook Huh H, Kim M, Byeon J, Han M, Lee H . Development and evaluation of a film-forming system hybridized with econazole-loaded nanostructured lipid carriers for enhanced antifungal activity against dermatophytes. Acta Biomater. 2019; 101:507-518. DOI: 10.1016/j.actbio.2019.10.024. View

20.

Gursoy R, Benita S . Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004; 58(3):173-82. DOI: 10.1016/j.biopha.2004.02.001. View